Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13,155,511
-
Total 13F shares
-
15,317,685
-
Share change
-
+7,474,645
-
Total reported value
-
$194,685,792
-
Put/Call ratio
-
46%
-
Price per share
-
$12.71
-
Number of holders
-
65
-
Value change
-
+$95,069,684
-
Number of buys
-
47
-
Number of sells
-
10
Institutional Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q3 2025
As of 30 Sep 2025,
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) was held by
65 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
15,317,685 shares.
The largest 10 holders included
BVF INC/IL, ORBIMED ADVISORS LLC, Nantahala Capital Management, LLC, Point72 Asset Management, L.P., Affinity Asset Advisors, LLC, Caligan Partners LP, Balyasny Asset Management L.P., SILVERARC CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, and RA CAPITAL MANAGEMENT, L.P..
This page lists
65
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.